WO2001005389A3 - N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase - Google Patents

N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase Download PDF

Info

Publication number
WO2001005389A3
WO2001005389A3 PCT/US2000/016323 US0016323W WO0105389A3 WO 2001005389 A3 WO2001005389 A3 WO 2001005389A3 US 0016323 W US0016323 W US 0016323W WO 0105389 A3 WO0105389 A3 WO 0105389A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonylaminiacid
metalloprteinase
inhibitors
derivatives
matrix metalloproteinase
Prior art date
Application number
PCT/US2000/016323
Other languages
French (fr)
Other versions
WO2001005389A2 (en
Inventor
William C Stallings
Huey S Shieh
Susan C Howard
Crecenzo Gary A De
Donald Joseph J Mc
Original Assignee
Searle & Co
William C Stallings
Huey S Shieh
Susan C Howard
Crecenzo Gary A De
Donald Joseph J Mc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co, William C Stallings, Huey S Shieh, Susan C Howard, Crecenzo Gary A De, Donald Joseph J Mc filed Critical Searle & Co
Priority to US10/031,181 priority Critical patent/US6869951B1/en
Priority to AU60498/00A priority patent/AU6049800A/en
Priority to PCT/US2000/021024 priority patent/WO2002003994A1/en
Priority to AU2000265100A priority patent/AU2000265100A1/en
Publication of WO2001005389A2 publication Critical patent/WO2001005389A2/en
Publication of WO2001005389A3 publication Critical patent/WO2001005389A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a matrix metalloproteinase inhibiting compound having structure (VIII) or a salt, an enantiomer, a diastereomer, a racemate, or a tautomer thereof. In other embodiments, the present invention provides a method of changing the conformation of a matrix metalloproteinase, a method of inhibiting a matrix metalloproteinase, and a method of treating osteoarthritis.
PCT/US2000/016323 1999-07-16 2000-07-12 N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase WO2001005389A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/031,181 US6869951B1 (en) 1999-07-16 2000-07-12 Method of changing conformation of a matrix metalloproteinase
AU60498/00A AU6049800A (en) 1999-07-16 2000-07-12 Method of changing conformation of a matrix metalloproteinase
PCT/US2000/021024 WO2002003994A1 (en) 2000-07-12 2000-08-01 N sulfonyl aminoacid derivatives as inhibitors of metalloproteinase
AU2000265100A AU2000265100A1 (en) 2000-07-12 2000-08-01 N sulfonyl aminoacid derivatives as inhibitors of metalloproteinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14413399P 1999-07-16 1999-07-16
US60/144,133 1999-07-16

Publications (2)

Publication Number Publication Date
WO2001005389A2 WO2001005389A2 (en) 2001-01-25
WO2001005389A3 true WO2001005389A3 (en) 2001-08-02

Family

ID=22507217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016323 WO2001005389A2 (en) 1999-07-16 2000-07-12 N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase

Country Status (2)

Country Link
AU (1) AU6049800A (en)
WO (1) WO2001005389A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000333A (en) 2001-02-14 2002-09-30 Warner Lambert Co DERIVATIVES OF ISOFTALIC ACID AS INHIBITORS OF METALOPROTEINASES OF THE MATRIX
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757037A2 (en) * 1995-07-28 1997-02-05 Ono Pharmaceutical Co., Ltd. Sulfonylamino acid derivatives as metalloproteinase inhibitors
EP0757984A1 (en) * 1995-08-08 1997-02-12 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives useful for inhibiting gelatinase
WO1998003166A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
WO1998039329A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Amidoaromatic ring sulfonamide hydroxamic acid compounds
WO1999042433A1 (en) * 1998-02-18 1999-08-26 Inha University Foundation Process for nitration of aromatic compounds using a non-acid type nitration process
JPH11236369A (en) * 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk Sulfonamide derivative and its production and pharmaceutical composition containing the same
JPH11246527A (en) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor
EP0950656A1 (en) * 1996-01-23 1999-10-20 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757037A2 (en) * 1995-07-28 1997-02-05 Ono Pharmaceutical Co., Ltd. Sulfonylamino acid derivatives as metalloproteinase inhibitors
EP0757984A1 (en) * 1995-08-08 1997-02-12 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives useful for inhibiting gelatinase
EP0950656A1 (en) * 1996-01-23 1999-10-20 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
WO1998003166A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
WO1998039329A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Amidoaromatic ring sulfonamide hydroxamic acid compounds
WO1999042433A1 (en) * 1998-02-18 1999-08-26 Inha University Foundation Process for nitration of aromatic compounds using a non-acid type nitration process
JPH11236369A (en) * 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk Sulfonamide derivative and its production and pharmaceutical composition containing the same
JPH11246527A (en) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIYAMA RYUICHI ET AL: "Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 10, 20 May 1999 (1999-05-20), pages 1723 - 1738, XP002159721, ISSN: 0022-2623 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 14 22 December 1999 (1999-12-22) *
TAMURA Y ET AL: "HIGHLY SELECTIVE AND ORALLY ACTIVE INHIBITORS OF TYPE IV COLLAGENASE (MMP-9 AND MMP-2): N-SULFONYLAMINO ACID DERIVATIVES", JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 41, no. 4, 1998, pages 640 - 649, XP002072052, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2001005389A2 (en) 2001-01-25
AU6049800A (en) 2001-02-05

Similar Documents

Publication Publication Date Title
WO2001005390A3 (en) Method for treating chronic pain using mek inhibitors
WO2004101562A3 (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
WO2001062726A3 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
HUP0203075A3 (en) Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
ZA200204397B (en) Nitrile derivatives as cathepsin K inhibitors.
WO2005021495A3 (en) Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
WO2001005391A3 (en) Method for treating chronic pain using mek inhibitors
WO2001014331A3 (en) Non-quinoline inhibitors of malaria parasites
AU2003250475A1 (en) 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
CA2470809A1 (en) 6-amino-morphinan derivatives, method of manufacturing them and their application
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
AU2003297197A1 (en) Method for increasing the efficacy of agricultural chemicals
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2000000198A8 (en) Piperidine derivatives having effects on serotonin related systems
IL144168A0 (en) 2,3,4,5,-tetrahydro-1h-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
WO2004032908A3 (en) Method of inhibiting angiogenesis
AU2001234730A1 (en) Method for inhibiting complement activation
AU2003249535A1 (en) 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2001005389A3 (en) N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase
EP1043311A4 (en) Biphenylamidine derivatives
AU2002214657A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
WO2001074391A1 (en) Preventives/remedies for kidney diseases
AU6726700A (en) Method of treating 1,1,1,3,3-pentafluoropropane
AU6558100A (en) Enzymatic method for killing or inhibiting microbial cells at high ph
HUP0002577A2 (en) Method for racemization of r,s-dioxo-benzyl-pyrrolopiperidine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10031181

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP